Narrow search
Showing 1 - 10 of 3,514
Cover Image
The Diffusion of Science-Driven Drug Discovery : Organizational Change in Pharmaceutical Research
Cockburn, Iain - 1999
Recent work linking the adoption of key organizational practices to productivity raises an important question: if adoption increases productivity so dramatically, why does adoption across an industry take so long? This paper explores this question in the context of one particularly interesting...
Persistent link: https://www.econbiz.de/10012471425
Cover Image
Drug Firms' Payments and Physicians' Prescribing Behavior in Medicare Part D
Carey, Colleen - 2020
In a pervasive but controversial practice, drug firms frequently make monetary or in-kind payments to physicians in the course of promoting prescription drugs. We use a federal database on the universe of such interactions between 2013 and 2015 linked to prescribing behavior in Medicare Part D....
Persistent link: https://www.econbiz.de/10012479275
Cover Image
Balancing Incentives : The Tension Between Basic and Applied Research
Cockburn, Iain - 1999
This paper presents empirical evidence that the intensity of research workers' incentives for the distinct tasks of basic and applied research are positively associated with each other. We relate this finding to the prediction of the theoretical literature that when effort is multi-dimensional,...
Persistent link: https://www.econbiz.de/10012471929
Cover Image
World Markets for Mergers and Acquisitions
Erel, Isil - 2009
Despite the fact that one-third of worldwide mergers involve firms from different countries, the vast majority of the academic literature on mergers studies domestic mergers. What little has been written about cross-border mergers has focused on public firms, usually from the United States. Yet,...
Persistent link: https://www.econbiz.de/10012463518
Cover Image
Mergers and Acquisitions in the Pharmaceutical and Biotech Industries
Danzon, Patricia Munch - 2004
mergers using propensity scores to control for merger endogeneity. Among large firms, we find that mergers are a response to … with mergers being a response to distress. Controlling for a firm's merger propensity, large firms that merged experienced … slower growth in operating profit in the third year following a merger. Thus mergers may be a response to trouble, but they …
Persistent link: https://www.econbiz.de/10012468157
Cover Image
Heterogeneous Globalization : Offshoring and Reorganization
Bernard, Andrew B. - 2020
This paper exploits a unique offshoring survey to show that firms continue domestic production of the same goods they offshore to low-wage countries. This shift towards "produced-good imports" coincides with a reallocation of labor from physical production to innovation and technology...
Persistent link: https://www.econbiz.de/10012482035
Cover Image
Are National Patent Laws the Blossoming Rain?
Qian, Yi - 2010
By thoroughly controlling for the country covariates, through a combination of matched sampling techniques with fixed-effect panel regression models, the analyses arrive at robust results across the various model specifications. First, national pharmaceutical patent protection alone does not...
Persistent link: https://www.econbiz.de/10012462357
Cover Image
Investments in Pharmaceuticals Before and After TRIPS
Kyle, Margaret - 2009
. Patent protection has increased around the world as a consequence of the TRIPS Agreement, which specifies minimum levels of … intellectual property protection for members of the World Trade Organization. It is generally argued that patents are critical for …
Persistent link: https://www.econbiz.de/10012463181
Cover Image
Scale, Scope and Spillovers : The Determinants of Research Productivity in the Pharmaceutical Industry
Henderson, Rebecca - 1993
This paper presents the results of a study of the determinants of research productivity in the pharmaceutical industry. Using disaggregated, internal firm data at the research program level from ten major pharmaceutical companies, we find no evidence of increasing returns to scale at either the...
Persistent link: https://www.econbiz.de/10012474480
Cover Image
Do "Reverse Payment" Settlements of Brand-Generic Patent Disputes in the Pharmaceutical Industry Constitute an Anticompetitive Pay for Delay?
Drake, Keith M. - 2014
Brand and generic drug manufacturers frequently settle patent litigation on terms that include a payment to the generic manufacturer along with a specified date at which the generic would enter the market. The Federal Trade Commission contends that these agreements extend the brand's market...
Persistent link: https://www.econbiz.de/10012458375